The in vivo electroporation instrument market is experiencing rapid growth with a projected compound annual growth rate (CAGR) of 6.1%. This advanced technology, which enables efficient gene transfer and cell manipulation in living organisms, is gaining significant traction in various research and clinical applications. The market is expected to reach a valuation of US$ 230.43 million by 2030, driven by the rising demand for innovative tools in genetic engineering, regenerative medicine, and drug delivery.
Sample link :
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4731

Key Highlights:
• In June 2021, Mirai Medical Ltd, a manufacturer of a precision cancer therapy platform, announced the first procedures at Rigshospitalet, University of Copenhagen, Denmark in a clinical trial to evaluate the safety of Calcium electroporation treatment with EndoVE®, and ePORE® a novel breakthrough technology that can treat gastrointestinal cancers endoscopically.
• In July 2021, Inovio Pharmaceuticals discovers, develops, and delivers a new generation of diseases, called DNA vaccines, focused on cancers and infectious diseases. The company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake.

Analyst view :
According to industry analysts, the in vivo electroporation instrument market is poised for substantial growth in the coming years. The increasing adoption of gene therapy, genetic engineering, and regenerative medicine techniques is driving the demand for advanced instruments that enable efficient in vivo electroporation. The ability to deliver genes and manipulate cells within living organisms holds immense potential for research and therapeutic applications. Analysts anticipate a promising future for the market, with a projected CAGR of 6.1% and a significant rise in market value, as researchers and clinicians continue to explore the vast possibilities of in vivo electroporation technology.
Competitive view :
The key players operating in the global In vivo electroporation instrument market includes Thermo Fisher Scientific, Inc., Merck, Lonza group, BEX, Celetrix LLC., Eppendorf AG, Harvard Bioscience Inc., Maxcyte Inc., Mirus Bio LLC, and Bio Rad laboratories. The companies are focusing on acquisitions and collaboration strategies to strengthen its market, which is expected to fuel the markets growth.

To know more
Contact Us:
Sales
Prophecy Market Insights
U.S. 1 860 531 2574
RoW: 917775049802
Email- [email protected]
Website- www.prophecymarketinsights.com
Blog- www.prophecyjournals